A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
- Determine the antitumor activity of topotecan in patients with persistent or recurrent
carcinoma of the cervix that failed higher priority treatment protocols.
- Determine the nature and degree of toxicity of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive topotecan IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28
days in the absence of disease progression or unacceptable toxicity.
Patient are followed for every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 22-60 patients will be accrued for this study within 1-2
Masking: Open Label, Primary Purpose: Treatment
James V. Fiorica, MD
Sarasota Memorial Hospital
United States: Federal Government
|University of Chicago Cancer Research Center||Chicago, Illinois 60637|
|Duke Comprehensive Cancer Center||Durham, North Carolina 27710|
|George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus||New Britain, Connecticut 06050|
|Kaiser Permanente Medical Center - Los Angeles||Los Angeles, California 90027|
|Holden Comprehensive Cancer Center at University of Iowa||Iowa City, Iowa 52242-1002|
|Charles M. Barrett Cancer Center at University Hospital||Cincinnati, Ohio 45267-0526|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|
|Cancer Care Associates - Midtown Tulsa||Tulsa, Oklahoma 74104|
|Women and Infants Hospital of Rhode Island||Providence, Rhode Island 02905|
|Yale Cancer Center||New Haven, Connecticut 06520-8028|
|Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center||Savannah, Georgia 31403-3089|
|William Beaumont Hospital - Royal Oak Campus||Royal Oak, Michigan 48073|
|Riverside Methodist Hospital Cancer Care||Columbus, Ohio 43214|
|Jonsson Comprehensive Cancer Center at UCLA||Los Angeles, California 90095-1781|
|Indiana University Melvin and Bren Simon Cancer Center||Indianapolis, Indiana 46202-5289|
|University of Mississippi Cancer Clinic||Jackson, Mississippi 39216-4505|
|Oklahoma University Cancer Institute||Oklahoma City, Oklahoma 73104|
|Methodist Estabrook Cancer Center||Omaha, Nebraska 68114-4199|
|Helen and Harry Gray Cancer Center at Hartford Hospital||Hartford, Connecticut 06102-5037|
|Mount Carmel Health - West Hospital||Columbus, Ohio 43222|
|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center||Columbus, Ohio 43210-1240|
|Lakeland Regional Cancer Center at Lakeland Regional Medical Center||Lakeland, Florida 33805|
|David L. Rike Cancer Center at Miami Valley Hospital||Dayton, Ohio 45409|
|Regional Cancer Center at Singing River Hospital||Pascagoula, Mississippi 39581|
|Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham||Birmingham, Alabama 35294|
|Saint Louis University Cancer Center||Saint Louis, Missouri 63110|
|Olive View - UCLA Medical Center Foundation||Sylmar, California 91342|